Posted On: 08/12/2014 8:12:57 PM
Post# of 63840
$AOLS climber. $0.51
called 9/21/13 $0.275
Website
10-Q 5/15/14
100% Buy
Shares Outstanding: 134.55M
Float: 33.38M
Tuesday, July 1, 2014
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard GasMarketwired( (Tue, Jul 1)
Wednesday, June 18, 2014
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin ExposureMarketwired( (Wed, Jun 18)
Monday, June 2, 2014
Aeolus Pharmateucticals to Present at LD Micro Invitational ConferenceMarketwired( (Mon, Jun 2)
Thursday, May 15, 2014
Aeolus Announces Second Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development ProgramMarketwired( (Thu, May 15)
Friday, February 14, 2014
Aeolus Announces First Quarter Fiscal Year 2014 Financial ResultsMarketwired( (Fri, Feb 14)
Thursday, February 13, 2014
Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New FormulationMarketwired( (Thu, Feb 13)
Monday, February 10, 2014
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy StudiesMarketwired( (Mon, Feb 10)
Thursday, January 23, 2014
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDAMarketwired( (Thu, Jan 23)
Monday, December 23, 2013
Aeolus Announces Fiscal Year 2013 Financial ResultsMarketwired( (Mon, Dec 23)
Thursday, December 5, 2013
Aeolus Files Application for New Patent on AEOL 10150Marketwired( (Thu, Dec 5)
Tuesday, October 29, 2013
Aeolus' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal RadiationMarketwired( (Tue, Oct 29)
Tuesday, September 17, 2013
BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation SyndromeMarketwired( (Tue, Sep 17)
Wednesday, September 11, 2013
Aeolus' AEOL 10150 Subject of $4.3 Million US Government Award for Protection Against Nerve Agents; Data Shows Drug Significantly Improves Survival in Animals Following Exposure to Pilocarpine, a Nerve Agent
called 9/21/13 $0.275
Website
10-Q 5/15/14
100% Buy
Shares Outstanding: 134.55M
Float: 33.38M
Tuesday, July 1, 2014
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard GasMarketwired( (Tue, Jul 1)
Wednesday, June 18, 2014
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin ExposureMarketwired( (Wed, Jun 18)
Monday, June 2, 2014
Aeolus Pharmateucticals to Present at LD Micro Invitational ConferenceMarketwired( (Mon, Jun 2)
Thursday, May 15, 2014
Aeolus Announces Second Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development ProgramMarketwired( (Thu, May 15)
Friday, February 14, 2014
Aeolus Announces First Quarter Fiscal Year 2014 Financial ResultsMarketwired( (Fri, Feb 14)
Thursday, February 13, 2014
Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New FormulationMarketwired( (Thu, Feb 13)
Monday, February 10, 2014
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy StudiesMarketwired( (Mon, Feb 10)
Thursday, January 23, 2014
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDAMarketwired( (Thu, Jan 23)
Monday, December 23, 2013
Aeolus Announces Fiscal Year 2013 Financial ResultsMarketwired( (Mon, Dec 23)
Thursday, December 5, 2013
Aeolus Files Application for New Patent on AEOL 10150Marketwired( (Thu, Dec 5)
Tuesday, October 29, 2013
Aeolus' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal RadiationMarketwired( (Tue, Oct 29)
Tuesday, September 17, 2013
BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation SyndromeMarketwired( (Tue, Sep 17)
Wednesday, September 11, 2013
Aeolus' AEOL 10150 Subject of $4.3 Million US Government Award for Protection Against Nerve Agents; Data Shows Drug Significantly Improves Survival in Animals Following Exposure to Pilocarpine, a Nerve Agent
(0)
(0)
